CURB-65: pneumonia severity
CURB-65: confusion, urea, respiratory rate, blood pressure and age 65 or over. 0 to 1 low risk, 2 intermediate, 3 or more high risk.
When to use
Adults with confirmed community-acquired pneumonia, when deciding where to treat.
Pearls and pitfalls
- Without urea (primary care, home visit), use CRB-65: same criteria minus urea.
- US labs report BUN: the cutoff is BUN > 19.6 mg/dL (= urea 7 mmol/L).
- Does not replace clinical judgment: hypoxemia, decompensated comorbidities or lack of support justify admission even with a low score.
- For ICU decisions, ATS/IDSA severe CAP criteria are more specific.
Fill in the fields to see the result.
Interpretation
- 0 to 1 point: Low risk (30-day mortality ~1.5%)
- Candidate for outpatient treatment if social situation and oral intake allow.
- 2 points: Intermediate risk (mortality ~9.2%)
- Short inpatient stay or closely supervised outpatient treatment.
- 3 to 5 points: High risk (mortality ~22%)
- Admit as severe pneumonia. With 4 or 5 points, assess for ICU.
Formula
1 point each: Confusion; Urea > 7 mmol/L (BUN > 19.6 mg/dL); RR ≥ 30/min; SBP < 90 or DBP ≤ 60 mmHg; age ≥ 65 years.
Evidence
Derived and validated in 1,068 patients from the UK, New Zealand and the Netherlands. Endorsed by BTS and NICE.
References
- Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-382. doi:10.1136/thorax.58.5.377
- Corrêa RA, Costa AN, Lundgren F, et al. Recomendações para o manejo da pneumonia adquirida na comunidade 2018. J Bras Pneumol. 2018;44(5):405-423. doi:10.1590/S1806-37562018000000130
Frequently asked questions
What is CURB-65?
CURB-65: confusion, urea, respiratory rate, blood pressure and age 65 or over. 0 to 1 low risk, 2 intermediate, 3 or more high risk. Adults with confirmed community-acquired pneumonia, when deciding where to treat.
When should I use CURB-65?
Adults with confirmed community-acquired pneumonia, when deciding where to treat.
How is CURB-65 calculated?
1 point each: Confusion; Urea > 7 mmol/L (BUN > 19.6 mg/dL); RR ≥ 30/min; SBP < 90 or DBP ≤ 60 mmHg; age ≥ 65 years.
How should the result be interpreted?
0 to 1 point: Low risk (30-day mortality ~1.5%). Candidate for outpatient treatment if social situation and oral intake allow. 2 points: Intermediate risk (mortality ~9.2%). Short inpatient stay or closely supervised outpatient treatment. 3 to 5 points: High risk (mortality ~22%). Admit as severe pneumonia. With 4 or 5 points, assess for ICU.
What are the limitations and pitfalls?
Without urea (primary care, home visit), use CRB-65: same criteria minus urea. US labs report BUN: the cutoff is BUN > 19.6 mg/dL (= urea 7 mmol/L). Does not replace clinical judgment: hypoxemia, decompensated comorbidities or lack of support justify admission even with a low score. For ICU decisions, ATS/IDSA severe CAP criteria are more specific.
What is the evidence behind it?
Derived and validated in 1,068 patients from the UK, New Zealand and the Netherlands. Endorsed by BTS and NICE. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-382.
Which calculators are related?
CKD-EPI 2021: eGFR: Estimates eGFR with the 2021 CKD-EPI creatinine equation, without a race coefficient, and reports the KDIGO G stage. Glasgow Coma Scale (with GCS-P): Assesses level of consciousness by eye, verbal and motor response, plus pupil reactivity (GCS-P). CRB-65: pneumonia outside hospital: Assesses community-acquired pneumonia prognosis without urea.
What are the sources?
Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-382. Corrêa RA, Costa AN, Lundgren F, et al. Recomendações para o manejo da pneumonia adquirida na comunidade 2018. J Bras Pneumol. 2018;44(5):405-423.